CELLINK granted Korean patent for ‘Clean Chamber’ bioprinting technology

The bioprinting company continues to strengthen protections of its unique bioprinting technologies

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Swedish bioprinting company CELLINK has been granted a patent from the Korean Intellectual Property Office for its Clean Chamber Technology, which enables bioprinting in a clean, sterile environment. The patent in question protects the technology—which is used in the company’s flagship BIO X and INKREDIBLE+ bioprinters—within the Korean market.

The patented technology by CELLINK is crucial to enabling desktop bioprinting while also ensuring sterility throughout the process—an important factor when producing anything related to the medical field. The patent from the Korean Intellectual Property Office helps to strengthen the company’s protection of its unique bioprinting platform and takes the company a step closer to its goal of protecting core technologies in the bioprinting field.

CELLINK Patent Korea clean chamber

“We are extremely excited to have another granted patent for our revolutionary technology platform,” said Erik Gatenholm, CEO of CELLINK. “As a globally recognized leader in the field, it is essential for us to protect our technologies so that we can continue to offer the most innovative solutions to our customers and collaborators around the world. The Clean Chamber Technology is a unique, value adding feature that ensures that the printing environment inside the Bioprinter is kept sterile so that the user can reduce the risk of contaminations and protect the precious cells during the printing process.”

CELLINK also says it is currently conducting the patenting process in other countries to expand protections on its unique technology. In February 2019, the bioprinting company was also granted a patent for a method of printing tissue constructions by the Swedish Patent and Registration Office.

The Gothenburg-based company also holds a patent for its Cellulose Nanofibrillar Bioink material for bioprinting applications in cell culturing, tissue engineering and regenerative medicine.

Composites AM 2024

746 composites AM companies individually surveyed and studied. Core composites AM market generated over $785 million in 2023. Market expected to grow to $7.8 billion by 2033 at 25.8% CAGR. This new...

Tess Boissonneault

Tess Boissonneault is a Montreal-based content writer and editor with five years of experience covering the additive manufacturing world. She has a particular interest in amplifying the voices of women working within the industry and is an avid follower of the ever-evolving AM sector. Tess holds a master's degree in Media Studies from the University of Amsterdam.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services


Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.